NCT05675033

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Serplulimab Combined With Anti-VEGF Antibody and Platinum-based Chemotherapy in Treat-naive EGFR/ALK-negative Advanced Lung Adenocarcinoma, a Single Arm Clinical Trail

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

In order to further evaluate the efficacy of immunotherapy combined with antivascular therapy in the real world, we used Serpluimab combined with Bevacizumab and platinum-based chemotherapy in previously untreated EGFR/ALK-negative advanced non-squamous NSCLC patients, to evaluate the efficacy and safety of this regimen.

Conditions

• Lung Adenocarcinoma
• Stage IV Non-small Cell Lung Cancer
• PD-1 Inhibitor
• VEGF

Interventions

Type	Name	Description
DRUG	Serplulimab and Bevacizumab injection	Serplulimab, 4.5mg/kg, intravenous injection, D1,Q21, until the disease progressed or showed intolerable side effects. Bevacizumab injection, 7.5mg/kg, intravenous injection, D1, Q21, until the disease progressed or showed intolerable side effects. Platinum-based chemotherapy: pemetrexed combined with carboplatin, D1-2, Q21, a total of 4 cycles.

Timeline

• Start date: 2023-01-10
• Primary completion: 2023-01-10
• Completion: 2024-01-10
• First posted: 2023-01-09
• Last updated: 2023-01-09